--- title: "Adicet Bio | 10-Q: FY2026 Q1 Revenue: USD 0" type: "News" locale: "en" url: "https://longbridge.com/en/news/286314467.md" datetime: "2026-05-13T20:38:53.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/286314467.md) - [en](https://longbridge.com/en/news/286314467.md) - [zh-HK](https://longbridge.com/zh-HK/news/286314467.md) generator: "portal-rs" --- # Adicet Bio | 10-Q: FY2026 Q1 Revenue: USD 0 Revenue: As of FY2026 Q1, the actual value is USD 0. EPS: As of FY2026 Q1, the actual value is USD -1.88, beating the estimate of USD -3.076. EBIT: As of FY2026 Q1, the actual value is USD -22.94 M. #### Operational Metrics ##### Net Loss Adicet Bio, Inc. reported a net loss of - $20.2 million for the three months ended March 31, 2026, which is a 28% decrease compared to a net loss of - $28.2 million for the same period in 2025. The accumulated deficit as of March 31, 2026, was $634.9 million. ##### Total Operating Expenses Total operating expenses were $21.57 million for the three months ended March 31, 2026, marking a decrease of $8.315 million or 28% from $29.885 million for the three months ended March 31, 2025. ##### Research and Development (R&D) Expenses Research and development expenses decreased by $5.327 million, or 23%, to $17.487 million for the three months ended March 31, 2026, from $22.814 million for the same period in 2025. This decrease was primarily due to a $3.6 million reduction in payroll and personnel expenses, a $1.4 million decrease in lab supplies and materials, a $0.5 million decrease in CRO expenses, and a $0.2 million decrease in allocated facility-related expenses, partially offset by a $0.4 million increase in professional fees. ###### External Program Expenses for Product Candidates (Segment Information) - **Prula-cel:** Expenses were $2.046 million for the three months ended March 31, 2026, down from $3.368 million for the same period in 2025. - **ADI-270:** Expenses were $0.369 million for the three months ended March 31, 2026, a decrease from $1.366 million for the same period in 2025. - **ADI-212:** Expenses increased to $0.948 million for the three months ended March 31, 2026, from $0.068 million for the same period in 2025. - **Total External Program Expenses:** Total external program expenses for product candidates were $3.363 million for the three months ended March 31, 2026, compared to $4.802 million for the same period in 2025. ##### General and Administrative (G&A) Expenses General and administrative expenses decreased by $3.0 million, or 42%, to $4.083 million for the three months ended March 31, 2026, from $7.071 million for the same period in 2025, primarily due to reductions in payroll and personnel-related expenses, allocated facility-related expenses, and professional fees. ##### Interest Income Interest income decreased by $0.3 million, or 20%, to $1.342 million for the three months ended March 31, 2026, from $1.683 million for the same period in 2025, mainly due to lower interest rates and cash balances. ##### Interest Expense Interest expense was - $0.023 million for the three months ended March 31, 2026, compared to $0 million for the same period in 2025. ##### Other Expense, Net Other expense, net, decreased by - $0.019 million, or 158%, for the three months ended March 31, 2026, compared to the same period in 2025, attributed to a decrease in state franchise taxes and realized losses related to foreign exchange rates. #### Cash Flow ##### Cash Flows from Operating Activities Net cash used in operating activities was - $21.49 million for the three months ended March 31, 2026, compared to - $25.397 million for the same period in 2025. ##### Cash Flows from Investing Activities Net cash provided by investing activities was $18.879 million for the three months ended March 31, 2026, primarily from $39.0 million in maturities of short-term treasury securities, partially offset by $20.1 million in purchases of short-term treasury securities and less than $0.1 million in purchases of property and equipment. In contrast, net cash used in investing activities was - $2.861 million for the three months ended March 31, 2025. ##### Cash Flows from Financing Activities Net cash used in financing activities was - $0.065 million for the three months ended March 31, 2026, and - $0.104 million for the same period in 2025, both primarily due to taxes withheld on net share settlement of equity awards. #### Unique Metrics ##### Cash, Cash Equivalents, and Short-Term Investments Adicet Bio, Inc. held $137.6 million in cash, cash equivalents, and short-term investments in treasury securities as of March 31, 2026. ##### Restricted Cash Restricted cash totaled $2.9 million as of March 31, 2026. #### Future Outlook and Strategy Adicet Bio, Inc. is focused on advancing its pipeline of allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, with its current cash, cash equivalents, and short-term investments expected to fund operating expenses and capital expenditures for at least the next twelve months. The company plans to meet with the FDA in the second quarter of 2026 to inform potential pivotal trial design for prula-cel, with initiation of start-up activities for a potential pivotal program expected in the second half of 2026. Additionally, Adicet Bio, Inc. anticipates submitting a regulatory filing for ADI-212 in the third quarter of 2026, with patient enrollment in a clinical trial expected to begin in the fourth quarter of 2026. ### Related Stocks - [ACET.US](https://longbridge.com/en/quote/ACET.US.md) ## Related News & Research - [Adicet Bio, Inc. (NASDAQ:ACET) Given Consensus Rating of "Moderate Buy" by Analysts](https://longbridge.com/en/news/296801308.md) - [Adicet Bio wins FDA IND clearance for ADI-212 prostate cancer trial](https://longbridge.com/en/news/297226436.md) - [Valion Bio announces 1-for-25 reverse stock split effective Aug. 31](https://longbridge.com/en/news/297186352.md) - [11:00 ETCizzle Bio Highlights CIZ1B Biomarker Blood Test for Lung Cancer at Next Generation Dx Summit](https://longbridge.com/en/news/297064751.md) - [Barinthus Bio sets 0.111 share exchange ratio for Clywedog deal](https://longbridge.com/en/news/296835612.md) --- > **Disclaimer: This article is for reference only and does not constitute any investment advice.**